# Myrobalan Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/myrobalan-therapeutics

- Industry: Biotechnology
- Headquarters: US
- Website: www.myrotx.com
- Total disclosed funding: $24M
- Latest round: Series A (Jan 10, 2024)
- Investors on record: 3

## About

Based in Massachusetts, US, and founded in 2021 by CEO Jing Wang, Zhigang He, and Guoping Feng, Myrobalan Therapeutics, Inc., a.k.a. Myrobalan Therapeutics operates as a developer of oral neurorestorative therapies aimed at reversing key pathologies underlying brain dysfunctions and CNS conditions. In January 2024, Myrobalan Therapeutics, Inc. raised USD 24 million in a Series A funding led by Co-Win Ventures, with participation from Guan Zi Equity Investment Partnership, 3E Bioventures Capital, and AB Magnitude Ventures Group.

The company’s product pipeline includes a CSF1R inhibitor that depletes maladaptive microglia, a GPR17 antagonist to promote remyelination in diseased or injured CNS, a TYK2 (tyrosine kinase 2) inhibitor to reduce neuroinflammation., and Program 4.

Myrobalan Therapeutics plans to use its proceeds from January 2024 funding to enable the company to advance its first program into the clinic.

## Funding rounds

- Series A, Jan 10, 2024, $24M — Co-Win Ventures, 3E Bioventures Capital, AB Magnitude Ventures Group

## Investors

- Co-Win Ventures (https://capitalatlas.ai/funds/co-win-ventures) — Series A
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series A
- AB Magnitude Ventures Group (https://capitalatlas.ai/funds/ab-magnitude-ventures-group) — Series A